Blood cancer

CAR-T cells attack cancer cells
#Autolus #Blood cancer #CAR-T #Cell therapy #Leukaemia #Oncology #University College London

Next-generation therapy overcomes limitations of other CAR-T

A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL).  The FELIX clinical trial was led by researchers at University College London (UCL) and UCLH and sponsored by UCL spin-out Autolus Therapeutics. Read More

#Cancer Research #Editor's Choice #News

Leukaemia
#Acute Myeloid Leukaemia #Blood cancer #Oncology #The Institute of Cancer Research

New target for acute myeloid leukaemia discovered

Researchers have identified a key weakness in acute myeloid leukaemia (AML), offering a promising new strategy to delay the progression of this aggressive blood cancer. The discovery focuses on disrupting the function of the nucleosome-remodelling factor (NURF) complex, which cancer cells, including leukaemia cells, rely on… Read More

#Cancer Research #Editor's Choice #News

#allogeneic cell therapies #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #Haematology

New DDW Highlights podcast: 24 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It’s been another busy week in the world of cell therapy, with the first… Read More

#News

#allogeneic cell therapies #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #Haematology

This week in drug discovery (17-21 June) 

News round-up for 17-21 June by DDW Senior Digital Content Editor Diana Spencer. It’s been another busy week in the world of cell therapy, with the first use of CAR-T therapy for stiff-person syndrome, a study debunking the risk of secondary cancers from CAR-T and a number of… Read More

#News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Multiple myeloma
#Blood cancer #Menarini #Myeloma #National Institute for Health and Care Excellence (NICE) #Oncology

Novel multiple myeloma drug recommended for UK NHS use

The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of Nexpovio (selinexor), in combination with bortezomib and dexamethasone, as a treatment for eligible multiple myeloma patients who have received one or two prior treatments. The recommendation follows recent NICE guidance recommending Nexpovio,… Read More

#News #Regulatory

CAR-T therapy
#Blood cancer #Leukaemia #National Institute for Health and Care Excellence (NICE) #Oncology #Paediatrics

UK’s NICE supports CAR-T for young people with leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kymriah (tisagenlecleucel) for treating paediatric and young adults up to the age of 25 with B-cell acute lymphoblastic leukaemia (ALL). It is approved in cancers that are refractory, in relapse post-transplant or in second or later relapse. The… Read More

#News #Regulatory

CAR-T therapy
#Blood cancer #Bristol Myers Squibb #CAR-T #Cell therapy #FDA #Leukaemia #Oncology

FDA approves first CAR-T cell therapy for relapsed CLL or SLL

The US Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It is approved in adult patients who have received at least two… Read More

#News #Regulatory #Trending News

Acute myeloid leukaemia
#Acute Myeloid Leukaemia #Blood cancer #Daiichi Sankyo #MHRA #Oncology

UK approves quizartinib for FLT3-ITD-positive AML

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Daiichi Sankyo's quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults with acute myeloid leukaemia (AML). Each year in the UK around 3,100 people are diagnosed with AML. Julian Beach, MHRA Interim Executive Director, Healthcare… Read More

#News #Regulatory

Blood samples in lab
#Blood cancer #CAR-T #Cell and gene therapy #Elicera Therapeutics #Phase I trial #Swedish Medical Products Agency

CAR-T therapy for B-cell lymphoma enters trials in Sweden

Cell and gene therapy company Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical Phase I/II study CARMA in patients with B-cell lymphoma who no longer respond to standard treatment or have relapsed. CARMA is a single-arm, unblinded, multicentre study… Read More

#Cancer Research #News

Blood cancer
#Blood cancer #Gene mutation #Nurix Therapeutics #Oncology #Protein degradation

Protein degrader overcomes resistance in B-cell malignancies

A paper in the journal Science has identified a new class of BTK mutations that are susceptible to NX-2127, a novel BTK and IKZF1/3 degrader.  The study ‘Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127’ elucidates a previously unappreciated oncogenic scaffold function… Read More

#Cancer Research #News

#Bispecific Antibodies #Blood cancer #Cancer research #CAR-T #JAK inhibitor #Oncology

This week in drug discovery (29 January – 2 February) 

News round-up for 29 January – 2 February by DDW Digital Content Editor Diana Spencer. Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of… Read More

#News

Stamp of approval
#Blood cancer #GSK #MHRA #Oncology #Rare disease

JAK inhibitor for rare blood cancer approved in Great Britain

GSK’s Omjjara (momelotinib) has been granted marketing authorisation in Great Britain for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. It is approved in patients who are Janus kinase (JAK)… Read More

#News #Regulatory

Blood cells
#Blood cancer #Gene mutation #Oncology #University of Cambridge #Wellcome Sanger Institute

Study reveals how genetic mutations combine to cause cancer

UK scientists have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. In the future, this knowledge could aid drug development and interventions that reduce the risk of disease. Researchers from the Wellcome Sanger Institute,… Read More

#Cancer Research #News

Cell and gene therapy
#Adverse event #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #FDA #Immunotherapy #ISCT #Oncology

Experts comment on FDA report on risk of T-cell malignancy  

The International Society for Cell & Gene Therapy (ISCT) has announced the publication in Nature Medicine of an expert consortium commentary addressing a recent statement from the US Food & Drug Administration (FDA) that it is investigating serious risk of T-cell malignancy in patients who received treatment with BCMA- or… Read More

#News #Regulatory

#American Society of Hematology #Blood cancer #Cancer research #CAR-T #Haematology #Oncology

New DDW Highlights podcast for 19 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Our news highlights this week focus on haematology, thanks in part to a number… Read More

#News